Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CCR1 | P32246 | 1/20 | 0.70 |
| ▸ | FERMT2 | Q96AC1 | 4/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | BACE1 | P56817 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3647594 | 0.92 | NR4A2 (1.00) | NR4A2CYP1A2CCR1FERMT2PKM | |
| SCHEMBL16013968 | 0.88 | CYP1A2 (0.72) | NR4A2CYP1A2CCR1FERMT2PKM | |
| SCHEMBL18281238 | 0.87 | CYP1A2 (0.70) | NR4A2CYP1A2CCR1FERMT2PKM | |
| SCHEMBL4213557 | 0.86 | NR4A2 (0.72) | NR4A2CYP1A2CCR1FERMT2PKM | |
| SCHEMBL8738060 | 0.85 | CYP1A2 (1.00) | NR4A2CYP1A2CCR1FERMT2PKM | |
| SCHEMBL23883153 | 0.83 | CCR1 (0.78) | NR4A2CYP1A2CCR1FERMT2BACE1 | |
| SCHEMBL1855080 | 0.83 | CYP1A2 (0.82) | NR4A2CYP1A2CCR1FERMT2PKM | |
| SCHEMBL17527057 | 0.81 | CCR1 (0.97) | NR4A2CYP1A2CCR1FERMT2KMT2A | |
| SCHEMBL15481296 | 0.81 | CCR1 (0.97) | NR4A2CYP1A2CCR1FERMT2KMT2A | |
| SCHEMBL18962393 | 0.81 | CYP1A2 (0.91) | NR4A2CYP1A2CCR1FERMT2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-08-16 | — | — | US | disclosed |
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-08-16 | — | — | US | disclosed |
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-08-16 | — | — | US | disclosed |
| EP-1771456-A2 | HYBRID QA MOLECULES WHEREIN Q IS AN AMINOQUINOLINE AND A IS AN ANTIBIOTIC RESIDUE, THEIR SYNTHESIS AND THEIR USES AS ANTIBACTERIAL AGENT | Palumed SA (FR) | 2007-04-11 | — | — | EP | disclosed |
| US-20070060558-A1 | Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents | PALUMED S.A. (FR) | 2007-03-15 | — | — | US | disclosed |
| WO-2006024741-A2 | HYBRID QA MOLECULES WHEREIN Q IS AN AMINOQUINOLINE AND A IS AN ANTIBIOTIC RESIDUE, THEIR SYNTHESIS AND THEIR USES AS ANTIBACTERIAL AGENT | PALUMED S.A. (FR) | 2006-03-09 | — | — | WO | disclosed |
| US-20060025327-A1 | Hybrid molecules QA, wherein Q is an aminoquinoline and a is an antibiotic or a resistance enzyme inhibitor, their synthesis and their uses as antibacterial agent | PALUMED S. A. & CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS | 2006-02-02 | — | — | US | disclosed |
| WO-2004026846-A1 | DNA-TARGETED BENZOTRIAZINE 1,4-DIOXIDES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | HIF1AN, HIF1A, HYOU1 | NR4A2 303/4885CYP1A2 1241/4885CCR1 2840/4885 |
| US-20070060558-A1 | Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents | QARS1, QPCT, QTRT2 | NR4A2 3836/4885CYP1A2 284/4885CCR1 4884/4885 |
| US-20060025327-A1 | Hybrid molecules QA, wherein Q is an aminoquinoline and a is an antibiotic or a resistance enzyme inhibitor, their synthesis and their uses as antibacterial agent | QARS1, QTRT1, QTRT2 | NR4A2 4057/4885CYP1A2 76/4885CCR1 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.